NCT02211989View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 14332 CL Powder in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

April 30, 2006

Conditions
Healthy
Interventions
DRUG

BI 14332 CL

DRUG

Placebo

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY